Stay updated with breaking news from Path Inc. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
UiPath (NYSE:PATH – Free Report) had its target price increased by Mizuho from $18.00 to $22.00 in a research report report published on Friday, Benzinga reports. The firm currently has a neutral rating on the healthcare company’s stock. A number of other analysts also recently commented on the company. Needham & Company LLC reiterated a […]
UiPath (NYSE:PATH – Free Report) had its price target boosted by Needham & Company LLC from $20.00 to $25.00 in a report released on Friday morning, Benzinga reports. The brokerage currently has a buy rating on the healthcare company’s stock. Several other equities analysts have also recently weighed in on PATH. Mizuho raised their price […]
UiPath (NYSE:PATH – Free Report) had its target price raised by BMO Capital Markets from $19.00 to $24.00 in a report published on Friday, Benzinga reports. The firm currently has a market perform rating on the healthcare company’s stock. A number of other brokerages have also issued reports on PATH. Canaccord Genuity Group lifted their […]
The CNN Money Fear and Greed index showed an improvement in overall market sentiment, while the index remained in the "Greed" zone on Friday. U.S. stocks closed higher on Friday, with the S&P 500 index jumping to a new closing high for 2023.
UiPath Inc. (NYSE:PATH – Get Free Report)’s share price gapped up prior to trading on Friday after JPMorgan Chase & Co. raised their price target on the stock from $19.00 to $22.00. The stock had previously closed at $19.76, but opened at $22.61. JPMorgan Chase & Co. currently has a neutral rating on the stock. […]